title: Uliginosin B presents antinociceptive effect mediated by dopaminergic and opioid systems in mice.
abstract: Previous studies have shown that uliginosin B inhibits dopamine reuptake in rat brain. This compound occurs in Hypericum polyanthemum and H. caprifoliatum for which was reported to have antinociceptive effect sensitive to naloxone. The aim of this study was to assess the antinociceptive effect of uliginosin B and to evaluate the involvement of opioid and dopaminergic receptors activation. Uliginosin B presented antinociceptive effect in hot-plate and abdominal writhing tests, in mice, at doses that did not impair the motor coordination (15 mg/kg, i.p.). Uliginosin B in high dose (90 mg/kg, i.p.) presented ataxic effect in the rotarod apparatus. These effects seem to be mediated by distinct receptors since the effect on the hot-plate was completely abolished by naloxone and sulpiride, but it was unaffected by SCH 23390. On the other hand, the motor impairment induced by uliginosin B was completely prevented by naloxone and partially prevented by sulpiride and SCH 23390. However, the receptors' activation appears to be indirect since uliginosin B did not bind to opioid and dopaminergic receptors. Thus, uliginosin B effects probably are due to its ability to inhibit monoamine reuptake with consequent activation of dopamine receptors and indirect stimulation of opioid system.
authors.affiliation: Programa de Pós-Graduação em Neurociências, Universidade Federal do Rio Grande do Sul, Avenida Ipiranga 2752/505c, 90610-000 Porto Alegre, RS, Brazil.
authors.forename: Eveline Dischkaln
authors.initials: ED
authors.lastname: Stolz
authors.forename: Alice Fialho
authors.initials: AF
authors.lastname: Viana
authors.forename: Diego Rafael
authors.initials: DR
authors.lastname: Hasse
authors.forename: Gilsane Lino
authors.initials: GL
authors.lastname: von Poser
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: do Rego
authors.forename: Stela M K
authors.initials: SM
authors.lastname: Rates
mesh_terms: D000700:Analgesics / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D018492:Dopamine Antagonists / Q000494:pharmacology; D004347:Drug Interactions; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D010147:Pain Measurement / Q000187:drug effects / Q000379:methods / Q000706:statistics & numerical data; D010696:Phloroglucinol / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D011869:Radioligand Assay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011954:Receptors, Dopamine / Q000378:metabolism*; D011957:Receptors, Opioid / Q000378:metabolism*; D045442:Rotarod Performance Test / Q000706:statistics & numerical data; D013469:Sulpiride / Q000494:pharmacology
chemical_list: D000700:Analgesics; D001552:Benzazepines; D018492:Dopamine Antagonists; D009292:Narcotic Antagonists; D011954:Receptors, Dopamine; D011957:Receptors, Opioid; C534628:SCH 23390; D009270:Naloxone; D013469:Sulpiride; D010696:Phloroglucinol; C547933:uliginosin B